Show simple item record

dc.contributor.authorGarassino, M C
dc.contributor.authorTorri, V
dc.contributor.authorMichetti, G
dc.contributor.authorLo Dico, M
dc.contributor.authorLa Verde, N
dc.contributor.authorAglione, S
dc.contributor.authorMancuso, A
dc.contributor.authorGallerani, E
dc.contributor.authorGaletta, D
dc.contributor.authorMartelli, O
dc.contributor.authorCollovà, E
dc.contributor.authorFatigoni, S
dc.contributor.authorGhidini, A
dc.contributor.authorSaggia, C
dc.contributor.authorBareggi, C
dc.contributor.authorRossi, A
dc.contributor.authorFarina, G
dc.contributor.authorThatcher, Nick
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorLorigan, Paul C
dc.contributor.authorCalifano, Raffaele
dc.date.accessioned2012-12-05T18:29:06Z
dc.date.available2012-12-05T18:29:06Z
dc.date.issued2011-06
dc.identifier.citationOutcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. 2011, 72 (3):378-83 Lung Canceren_GB
dc.identifier.issn1872-8332
dc.identifier.pmid20950888
dc.identifier.doi10.1016/j.lungcan.2010.09.009
dc.identifier.urihttp://hdl.handle.net/10541/254643
dc.description.abstractPatients with small-cell lung cancer (SCLC) that progress after first-line chemotherapy have a poor prognosis and the evidence of a benefit from second-line (SL) chemotherapy is limited. Patients relapsing or progressing more than 90 days after completion of first-line treatment are considered platinum sensitive and may be rechallenged with platinum-based chemotherapy. Topotecan is approved as SL treatment independent of time to progression. This retrospective analysis evaluates the clinical outcomes of SCLC patients who received SL chemotherapy after platinum-etoposide chemotherapy.
dc.language.isoenen
dc.rightsArchived with thanks to Lung cancer (Amsterdam, Netherlands)en_GB
dc.subject.meshAged
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshEtoposide
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPlatinum
dc.subject.meshRetrospective Studies
dc.subject.meshSmall Cell Lung Carcinoma
dc.subject.meshSurvival Analysis
dc.subject.meshTopotecan
dc.subject.meshTreatment Outcome
dc.titleOutcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.en
dc.typeArticleen
dc.contributor.departmentOncology Department, Ospedale Fatebenefratelli e Oftalmico, Milano, Italy.en_GB
dc.identifier.journalLung Canceren_GB
html.description.abstractPatients with small-cell lung cancer (SCLC) that progress after first-line chemotherapy have a poor prognosis and the evidence of a benefit from second-line (SL) chemotherapy is limited. Patients relapsing or progressing more than 90 days after completion of first-line treatment are considered platinum sensitive and may be rechallenged with platinum-based chemotherapy. Topotecan is approved as SL treatment independent of time to progression. This retrospective analysis evaluates the clinical outcomes of SCLC patients who received SL chemotherapy after platinum-etoposide chemotherapy.


Files in this item

This item appears in the following Collection(s)

Show simple item record